Your browser doesn't support javascript.
loading
Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse.
Miró, Òscar; Galicia, Miguel; Dargan, Paul; Dines, Alison M; Giraudon, Isabelle; Heyerdahl, Fridtjof; Hovda, Knut E; Yates, Christopher; Wood, David M; Liakoni, Evangelia; Liechti, Matthias; Jürgens, Gesche; Pedersen, Carsten Boe; O'Connor, Niall; Markey, Gerard; Moughty, Adrian; Lee, Christopher; O'Donohoe, Patrick; Sein Anand, Jacek; Puiguriguer, Jordi; Homar, Catalina; Eyer, Florian; Vallersnes, Odd Martin; Persett, Per Sverre; Chevillard, Lucie; Mégarbane, Bruno; Paasma, Raido; Waring, W Stephen; Põld, Kristiina; Rabe, Christian; Kabata, Piotr Maciej.
Afiliación
  • Miró Ò; Emergency Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain.
  • Galicia M; Emergency Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: mgalicia@clinic.cat.
  • Dargan P; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK; Clinical Toxicology, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • Dines AM; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK.
  • Giraudon I; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
  • Heyerdahl F; The National CBRNe Centre of Medicine, Department of Acute Medicine, Medical Division, Oslo University Hospital, Oslo, Norway.
  • Hovda KE; The National CBRNe Centre of Medicine, Department of Acute Medicine, Medical Division, Oslo University Hospital, Oslo, Norway.
  • Yates C; Emergency Department and Clinical Toxicology Unit, Hospital Universitari Son Espases, Mallorca, Spain.
  • Wood DM; Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK; Clinical Toxicology, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • Liakoni E; Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Division of Clinical Pharmacology and Toxicology, Basel University Hospital and University of Basel, Switzerland.
  • Liechti M; Division of Clinical Pharmacology and Toxicology, Basel University Hospital and University of Basel, Switzerland.
  • Jürgens G; Zealand University Hospital Roskilde Clinical Pharmacology Unit Roskilde, Denmark.
  • Pedersen CB; Department of Anaesthesia University Hospital of Zealand, Køge, Denmark.
  • O'Connor N; Department of Emergency Medicine, Our Lady of Lourdes Hospital, Drogheda, County Louth, Republic of Ireland.
  • Markey G; Department of Emergency Medicine, Our Lady of Lourdes Hospital, Drogheda, County Louth, Republic of Ireland.
  • Moughty A; Emergency Department Mater Misericordiae University Hospital, Dublin 7, Republic of Ireland.
  • Lee C; Emergency Department Mater Misericordiae University Hospital, Dublin 7, Republic of Ireland.
  • O'Donohoe P; Emergency Department Mater Misericordiae University Hospital, Dublin 7, Republic of Ireland.
  • Sein Anand J; Department of Clinical Toxicology Medical University of Gdansk, Gdansk, Poland; Pomeranian Centre of Toxicology, Gdansk, Poland.
  • Puiguriguer J; Clinical Toxicology Unit Emergency Department, Hospital Son Espases, Palma de Mallorca, Balearic Island, Spain.
  • Homar C; Clinical Toxicology Unit Emergency Department, Hospital Son Espases, Palma de Mallorca, Balearic Island, Spain.
  • Eyer F; Department of Clinical Toxicology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Vallersnes OM; Department of General Practice, University of Oslo, Oslo, Norway; Oslo Accident and Emergency Outpatient Clinic, City of Oslo Health Agency, Oslo, Norway.
  • Persett PS; Department of Acute Medicine, Medical Division, Oslo University Hospital, Oslo, Norway.
  • Chevillard L; Department of Medical and Toxicological Critical Care, Lariboisière Hospital, INSERM UMRS-1144, Paris-Diderot University, Paris, France.
  • Mégarbane B; Department of Medical and Toxicological Critical Care, Lariboisière Hospital, INSERM UMRS-1144, Paris-Diderot University, Paris, France.
  • Paasma R; Foundation Pärnu Hospital, Pärnu, Estonia.
  • Waring WS; Acute Medical Unit York Teaching Hospitals NHS Foundation Trust York, UK.
  • Põld K; Emergency Medicine Department North-Estonia Medical Centre Tallinn, Estonia.
  • Rabe C; Department of Clinical Toxicology, Klinikum rechts der Isar, Technical University of Munich, Germany.
  • Kabata PM; Pomeranian Centre of Toxicology, Gdansk, Poland; Medical University Gdansk, Department of Clinical Toxicology, Gdansk, Poland.
Toxicol Lett ; 277: 84-91, 2017 Aug 05.
Article en En | MEDLINE | ID: mdl-28579487
ABSTRACT

OBJECTIVE:

To study the profile of European gamma-hydroxybutyrate (GHB) and gammabutyrolactone (GBL) intoxication and analyse the differences in the clinical manifestations produced by intoxication by GHB/GBL alone and in combination with other substances of abuse.

METHOD:

We prospectively collected data on all the patients attended in the Emergency Departments (ED) of the centres participating in the Euro-DEN network over 12 months (October 2013 to September 2014) with a primary presenting complaint of drug intoxication (excluding ethanol alone) and registered the epidemiological and clinical data and outcomes.

RESULTS:

We included 710 cases (83% males, mean age 31 years), representing 12.6% of the total cases attended for drug intoxication. Of these, 73.5% arrived at the ED by ambulance, predominantly during weekend, and 71.7% consumed GHB/GBL in combination with other substances of abuse, the most frequent additional agents being ethanol (50%), amphetamine derivatives (36%), cocaine (12%) and cannabis (8%). Among 15 clinical features pre-defined in the project database, the 3 most frequently identified were altered behaviour (39%), reduced consciousness (34%) and anxiety (14%). The severity ranged from mild cases requiring no treatment (308 cases, 43.4%) to severe cases requiring admission to intensive care (103 cases, 14.6%) and mechanical ventilation (49 cases, 6.9%). No deaths were reported. In comparison with only GHB/GBL consumption, patients consuming GHB/GBL with co-intoxicants presented more vomiting (15% vs. 3%, p<0.001) and cardiovascular symptoms (5.3% vs. 1.5%, p<0.05), a greater need for treatment (59.8% vs. 48.3%, p<0.01) and a longer ED stay (11.3% vs. 3.6% patients with ED stay >12h, p<0.01).

CONCLUSIONS:

The profile of the typical GHB/GBL-intoxicated European is a young male, requiring care for altered behaviour and reduced level of consciousness, mainly during the weekend. The clinical features are more severe when GHB is consumed in combination with other substances of abuse.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oxibato de Sodio / 4-Butirolactona / Drogas Ilícitas / Trastornos Relacionados con Sustancias / Sobredosis de Droga Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Toxicol Lett Año: 2017 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oxibato de Sodio / 4-Butirolactona / Drogas Ilícitas / Trastornos Relacionados con Sustancias / Sobredosis de Droga Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Toxicol Lett Año: 2017 Tipo del documento: Article País de afiliación: España